You are currently on the new version of our website. Access the old version .

91 Results Found

  • Article
  • Open Access
815 Views
20 Pages

Integrative Neoepitope Discovery in Glioblastoma via HLA Class I Profiling and AlphaFold2-Multimer

  • Raquel Francés,
  • Jenny Bonifacio-Mundaca,
  • Íñigo Casafont,
  • Christophe Desterke and
  • Jorge Mata-Garrido

Background/Objectives: Glioblastoma multiforme (GBM) is an aggressive primary brain tumor with limited therapeutic options. Neoantigen-based immunotherapy offers a promising avenue, but its efficacy primarily depends on the ability of somatic mutatio...

  • Review
  • Open Access
7 Citations
8,829 Views
15 Pages

31 March 2025

Personalized cancer vaccines are a promising immunotherapy targeting patient-specific tumor neoantigens, yet their design and efficacy remain challenging. Recent advances in artificial intelligence (AI) provide powerful tools to enhance multiple stag...

  • Perspective
  • Open Access
3 Citations
3,956 Views
20 Pages

17 December 2024

Recombinant antibodies and, more recently, T cell receptor (TCR)-engineered T cell therapies represent two immunological strategies that have come to the forefront of clinical interest for targeting intracellular neoantigens in benign and malignant d...

  • Article
  • Open Access
6 Citations
3,677 Views
13 Pages

Identification of an Immunogenic Medulloblastoma-Specific Fusion Involving EPC2 and GULP1

  • Claudia Paret,
  • Nadine Lehmann,
  • Hannah Bender,
  • Maximilian Sprang,
  • Clemens J. Sommer,
  • Denis Cana,
  • Larissa Seidmann,
  • Arthur Wingerter,
  • Marie A. Neu and
  • Joerg Faber
  • + 7 authors

21 November 2021

Medulloblastoma is the most common malignant brain tumor in children. Immunotherapy is yet to demonstrate dramatic results in medulloblastoma, one reason being the low rate of mutations creating new antigens in this entity. In tumors with low mutatio...

  • Article
  • Open Access
29 Citations
9,514 Views
14 Pages

Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations

  • Susumu Iiizumi,
  • Junya Ohtake,
  • Naoko Murakami,
  • Taku Kouro,
  • Mamoru Kawahara,
  • Fumiko Isoda,
  • Hiroshi Hamana,
  • Hiroyuki Kishi,
  • Norihiro Nakamura and
  • Tetsuro Sasada

24 February 2019

Neoantigens derived from tumor-specific genetic mutations might be suitable targets for cancer immunotherapy because of their high immunogenicity. In the current study, we evaluated the immunogenicity of 10 driver mutations that are frequently expres...

  • Review
  • Open Access
46 Views
18 Pages

Peptide Arrays as Tools for Unraveling Tumor Microenvironments and Drug Discovery in Oncology

  • Anna Grab,
  • Christoph Reißfelder and
  • Alexander Nesterov-Mueller

14 January 2026

Peptide arrays represent a powerful tool for investigating a wide application field for biomedical questions. This review summarizes recent applications of peptide chips in oncology, with a focus on tumor microenvironment, metastasis, and drug mechan...

  • Review
  • Open Access
906 Views
13 Pages

Peptide Vaccines for Pediatric High-Grade Glioma and Diffuse Midline Glioma: Current Progress and Future Perspectives

  • Aron K. Mebrahtu,
  • Vatsal Jain,
  • Eliese M. Moelker,
  • Alexandra M. Hoyt-Miggelbrink,
  • Katayoun Ayasoufi and
  • Eric M. Thompson

30 November 2025

High-grade gliomas (HGGs) and diffuse midline gliomas (DMGs) in pediatric patients carry a poor prognosis, necessitating the rapid development of novel therapies. Peptide vaccines represent a safe, repeatable, and rational immunotherapeutic modality...

  • Article
  • Open Access
6 Citations
4,095 Views
13 Pages

Denovo-GCN: De Novo Peptide Sequencing by Graph Convolutional Neural Networks

  • Ruitao Wu,
  • Xiang Zhang,
  • Runtao Wang and
  • Haipeng Wang

5 April 2023

The de novo peptide-sequencing method can be used to directly infer the peptide sequence from a tandem mass spectrum. It has the advantage of not relying on protein databases and plays a key role in the determination of the protein sequences of unkno...

  • Article
  • Open Access
1 Citations
2,329 Views
9 Pages

A Universal Antigen-Ranking Method to Design Personalized Vaccines Targeting Neoantigens against Melanoma

  • Iker Malaina,
  • Luis Martínez,
  • Juan Manuel Montoya,
  • Santos Alonso,
  • María Dolores Boyano,
  • Aintzane Asumendi,
  • Rosa Izu,
  • Ana Sanchez-Diez,
  • Goikoane Cancho-Galan and
  • Ildefonso M. de la Fuente

5 January 2023

Background: The main purpose of this article is to introduce a universal mathematics-aided vaccine design method against malignant melanoma based on neoantigens. The universal method can be adapted to the mutanome of each patient so that a specific c...

  • Article
  • Open Access
5 Citations
5,847 Views
15 Pages

3 October 2020

In some instances, when chemicals bind to proteins, they have the potential to induce a conformational change in the macromolecule that may misfold in such a way that makes it similar to the various target sites or act as a neoantigen without conform...

  • Review
  • Open Access
6 Citations
8,824 Views
32 Pages

Peptide Vaccines as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape

  • Manju Lekshmy,
  • Chandrasekharan Rajalekshmi Dhanya,
  • Jayashree SatheeshKumar Smrithi,
  • Janaki Anandavallyamma Sindhurani,
  • Jiji Joseph Vandanamthadathil,
  • Jayakrishnan Therthala Veettil,
  • Leelamma Anila,
  • Vishnu Sasidharan Lathakumari,
  • Adhira M. Nayar and
  • Maya Madhavan

24 July 2023

Breast and gynecologic cancers are significant global threats to women’s health and those living with the disease require lifelong physical, financial, and social support from their families, healthcare providers, and society as a whole. Cancer...

  • Review
  • Open Access
14 Citations
3,106 Views
23 Pages

Peptide antigens derived from tumors have been observed to elicit protective immune responses, categorized as either tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs). Subunit cancer vaccines incorporating these antigens have shown p...

  • Opinion
  • Open Access
6 Citations
3,405 Views
13 Pages

Activation of DNA Damage Tolerance Pathways May Improve Immunotherapy of Mesothelioma

  • Hélène Brossel,
  • Alexis Fontaine,
  • Clotilde Hoyos,
  • Majeed Jamakhani,
  • Mégane Willems,
  • Malik Hamaidia and
  • Luc Willems

27 June 2021

Immunotherapy based on two checkpoint inhibitors (ICI), programmed cell death 1 (PD-1, Nivolumab) and cytotoxic T-lymphocyte 4 (CTLA-4, Ipilimumab), has provided a significant improvement in overall survival for malignant mesothelioma (MM). Despite t...

  • Systematic Review
  • Open Access
1 Citations
2,354 Views
15 Pages

The Efficacy of Neoantigen-Loaded Dendritic Cell Vaccine Immunotherapy in Non-Metastatic Gastric Cancer

  • Menelaos Papakonstantinou,
  • Paraskevi Chatzikomnitsa,
  • Areti Danai Gkaitatzi,
  • Athanasia Myriskou,
  • Alexandros Giakoustidis,
  • Dimitrios Giakoustidis and
  • Vasileios N. Papadopoulos

Introduction: Gastric cancer (GC) is the third leading cause of cancer-related deaths worldwide. Even though surgery and chemotherapy are the mainstay of treatment, immunotherapy, and more specifically anti-tumor vaccination, has gained popularity ov...

  • Article
  • Open Access
3 Citations
3,583 Views
15 Pages

22 December 2023

There are numerous clinically proven methods for treating cancer worldwide. Immunotherapy has been used to treat cancer with significant success in the current studies. The purpose of this work is to identify somatically altered target gene neoantige...

  • Article
  • Open Access
1 Citations
733 Views
16 Pages

Molecular Insights into Tumor Immunogenicity

  • Irini Doytchinova,
  • Stanislav Sotirov and
  • Ivan Dimitrov

Tumor immunogenicity depends on the ability of peptides to form stable and specific interactions with both HLA molecules and T-cell receptors (TCRs). While HLA binding is essential, not all HLA-binding peptides elicit T-cell responses. This study inv...

  • Feature Paper
  • Review
  • Open Access
43 Citations
22,531 Views
20 Pages

Evolution of CD8+ T Cell Receptor (TCR) Engineered Therapies for the Treatment of Cancer

  • Yimo Sun,
  • Fenge Li,
  • Heather Sonnemann,
  • Kyle R. Jackson,
  • Amjad H. Talukder,
  • Arjun S. Katailiha and
  • Gregory Lizee

10 September 2021

Engineered T cell receptor T (TCR-T) cell therapy has facilitated the generation of increasingly reliable tumor antigen-specific adaptable cellular products for the treatment of human cancer. TCR-T cell therapies were initially focused on targeting s...

  • Review
  • Open Access
10 Citations
4,159 Views
12 Pages

21 December 2022

The impressive clinical success of cancer immunotherapy has motivated the continued search for new targets that may serve to guide potent effector functions in an attempt to efficiently kill malignant cells. The intracellular proteome is an interesti...

  • Article
  • Open Access
4 Citations
3,036 Views
18 Pages

Effect of Secretion Efficiency of Mutant KRAS Neoantigen by Lactococcus lactis on the Immune Response of a Mucosal Vaccine Delivery Vehicle Targeting Colorectal Cancer

  • Nur Aqlili Riana Alias,
  • Winfrey Pui Yee Hoo,
  • Pui Yan Siak,
  • Siti Sarah Othman,
  • Noorjahan Banu Mohammed Alitheen,
  • Lionel Lian Aun In,
  • Raha Abdul Rahim and
  • Adelene Ai-Lian Song

Colorectal cancer (CRC) is often caused by mutations in the KRAS oncogene, making KRAS neoantigens a promising vaccine candidate for immunotherapy. Secreting KRAS antigens using live Generally Recognized as Safe (GRAS) vaccine delivery hosts such as...

  • Communication
  • Open Access
5 Citations
3,348 Views
11 Pages

6 March 2023

(1) Background: EWS fusion genes are associated with Ewing sarcoma and other Ewing family tumors including desmoplastic small round tumor, DSRCT. We utilize a clinical genomics workflow to reveal real-world frequencies of EWS fusion events, catalogin...

  • Review
  • Open Access
14 Citations
4,267 Views
16 Pages

15 February 2023

This review summarizes recent development in synthetic drugs and biologics targeting intracellular driver genes in epithelial cancers, focusing on KRAS, and provides a current perspective and potential leads for the field. Compared to biologics, smal...

  • Review
  • Open Access
21 Citations
4,886 Views
14 Pages

Harnessing the Immune System with Cancer Vaccines: From Prevention to Therapeutics

  • Ilene Le,
  • Subramanian Dhandayuthapani,
  • Jessica Chacon,
  • Anna M. Eiring and
  • Shrikanth S. Gadad

Prophylactic vaccination against infectious diseases is one of the most successful public health measures of our lifetime. More recently, therapeutic vaccination against established diseases such as cancer has proven to be more challenging. In the ho...

  • Review
  • Open Access
16 Citations
5,313 Views
21 Pages

Collagen type II (COL2), the main structural protein of hyaline cartilage, is considerably affected by autoimmune responses associated with the pathogenesis of rheumatoid arthritis (RA). Posttranslational modifications (PTMs) play a significant role...

  • Article
  • Open Access
9 Citations
3,968 Views
15 Pages

A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma

  • Alexandre Harari,
  • Apostolos Sarivalasis,
  • Kaat de Jonge,
  • Anne-Christine Thierry,
  • Florian Huber,
  • Caroline Boudousquie,
  • Laetitia Rossier,
  • Angela Orcurto,
  • Martina Imbimbo and
  • Lana E. Kandalaft
  • + 1 author

18 November 2021

Endometrial cancer (EC) is a common gynecological malignancy and the fourth most common malignancy in European and North American women. Amongst EC, the advanced serous, p53-mutated, and pMMR subtypes have the highest risk of relapse despite optimal...

  • Article
  • Open Access
1,981 Views
17 Pages

Accelerating Neoantigen Discovery: A High-Throughput Approach to Immunogenic Target Identification

  • Lena Pfitzer,
  • Gitta Boons,
  • Lien Lybaert,
  • Wim van Criekinge,
  • Cedric Bogaert and
  • Bruno Fant

15 August 2025

Background: Antigen-targeting immunotherapies hinge on the accurate identification of immunogenic epitopes that elicit robust T-cell responses. However, current computational approaches focus primarily on MHC binding affinity, leading to high false-p...

  • Article
  • Open Access
5 Citations
6,552 Views
12 Pages

18 January 2022

T cell-mediated adaptive immunity plays a key role in immunological surveillance and host control of infectious diseases. A better understanding of T cell receptor (TCR) recognition of pathogen-derived epitopes or cancer-associated neoantigens is the...

  • Review
  • Open Access
2,432 Views
13 Pages

Advances in Non-Small Cell Lung Cancer Cellular Immunotherapy: A Progress in Dendritic Cell, T-Cell, and NK Cell Vaccines

  • Mirza Masroor Ali Beg,
  • Mohammad Aslam,
  • Asma Ayaz,
  • Muhammad Saeed Akhtar and
  • Wajid Zaman

16 September 2025

Over the past decade, cellular immunotherapy has emerged as a transformative strategy for non-small cell lung cancer (NSCLC), with dendritic-cell (DC) vaccines, T-cell vaccines, and natural killer (NK)-cell therapies demonstrating distinct mechanisms...

  • Review
  • Open Access
3 Citations
3,479 Views
21 Pages

Vaccine-Based Immunotherapy for Oropharyngeal and Nasopharyngeal Cancers

  • Daria Maria Filippini,
  • Elisabetta Broseghini,
  • Carlotta Liberale,
  • Giulia Gallerani,
  • Giambattista Siepe,
  • Elisabetta Nobili,
  • Manuela Ferracin and
  • Gabriele Molteni

11 February 2025

Viral infections such as human papillomavirus (HPV) and Epstein–Barr virus (EBV) play a critical role in the onset of oropharyngeal (OPC) and nasopharyngeal cancer (NPC), respectively. Despite advancements in targeted therapies and immunotherap...

  • Review
  • Open Access
2 Citations
4,078 Views
47 Pages

Cancer Vaccination and Immune-Based Approaches in Pancreatic Cancer

  • Matthew Bloom,
  • Ali Raza Shaikh,
  • Zhengyang Sun,
  • Babar Bashir and
  • Adam E. Snook

15 July 2025

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with high recurrence rates even after curative resection and adjuvant chemotherapy. Although immunotherapeutic approaches, such as immune checkpoint blockade (ICB), have revolutioniz...

  • Review
  • Open Access
4 Citations
2,958 Views
28 Pages

Background: Cancer immunotherapy has advanced, yet therapeutic resistance and low response rates remain problematic. This study explores histone deacetylase inhibitors (HDACis) as adjuvants for cancer vaccines to enhance anti-tumor immunity and overc...

  • Article
  • Open Access
12 Citations
4,535 Views
17 Pages

An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML

  • Dyantha I. van der Lee,
  • Georgia Koutsoumpli,
  • Rogier M. Reijmers,
  • M. Willy Honders,
  • Rob C. M. de Jong,
  • Dennis F. G. Remst,
  • Tassilo L. A. Wachsmann,
  • Renate S. Hagedoorn,
  • Kees L. M. C. Franken and
  • Marieke Griffioen
  • + 9 authors

27 October 2021

Acute myeloid leukemia (AML) is a hematological malignancy caused by clonal expansion of myeloid progenitor cells. Most patients with AML respond to chemotherapy, but relapses often occur and infer a very poor prognosis. Thirty to thirty-five percent...

  • Article
  • Open Access
1 Citations
3,401 Views
12 Pages

19 November 2022

The poly(A)-binding protein cytoplasmic 1 (PAB1 or PABPC1) protein is associated with the long poly(A) mRNA tails, inducing stability. Herein, we investigated the dynamics of the PABPC1 protein, along with tracing its mRNA binding specificity. During...

  • Review
  • Open Access
11 Citations
8,540 Views
12 Pages

MR1-Restricted T Cells in Cancer Immunotherapy

  • Pedro Flores-Villanueva,
  • Navid Sobhani,
  • Xu Wang and
  • Yong Li

3 August 2020

Major histocompatibility complex class I-related (MR1) was first identified as a cell membrane protein involved in the development and expansion of a unique set of T cells expressing an invariant T-cell receptor (TCR) α-chain. These cells were...

  • Article
  • Open Access
5 Citations
5,895 Views
15 Pages

Ropporin-1 and 1B Are Widely Expressed in Human Melanoma and Evoke Strong Humoral Immune Responses

  • Jessica Da Gama Duarte,
  • Katherine Woods,
  • Luke T. Quigley,
  • Cyril Deceneux,
  • Candani Tutuka,
  • Tom Witkowski,
  • Simone Ostrouska,
  • Chris Hudson,
  • Simon Chang-Hao Tsao and
  • Andreas Behren
  • + 3 authors

9 April 2021

Antibodies that block immune regulatory checkpoints (programmed cell death 1, PD-1 and cytotoxic T-lymphocyte-associated antigen 4, CTLA-4) to mobilise immunity have shown unprecedented clinical efficacy against cancer, demonstrating the importance o...

  • Review
  • Open Access
29 Citations
8,490 Views
16 Pages

26 January 2021

The CD137 receptor (4-1BB, TNF RSF9) is an activation induced molecule expressed by antigen-specific T-cells. The engagement with its ligand, CD137L, is capable of increasing T-cell survival, proliferation, and cytokine production. This allowed to id...

  • Review
  • Open Access
909 Views
20 Pages

28 November 2025

Type 1 diabetes mellitus (T1DM) is an autoimmune disease caused by the destruction of insulin-producing pancreatic β-cells by autoreactive T cells. Current treatments, including insulin replacement therapy and various immunotherapies, often modu...

  • Review
  • Open Access
13 Citations
6,549 Views
18 Pages

Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia

  • Fabio Forghieri,
  • Giovanni Riva,
  • Ivana Lagreca,
  • Patrizia Barozzi,
  • Francesca Bettelli,
  • Ambra Paolini,
  • Vincenzo Nasillo,
  • Beatrice Lusenti,
  • Valeria Pioli and
  • Mario Luppi
  • + 14 authors

25 August 2021

The C-terminal aminoacidic sequence from NPM1-mutated protein, absent in normal human tissues, may serve as a leukemia-specific antigen and can be considered an ideal target for NPM1-mutated acute myeloid leukemia (AML) immunotherapy. Different in si...

  • Article
  • Open Access
8 Citations
3,932 Views
13 Pages

4 September 2021

Aluminum is in our water and food, and is used as an adjuvant in vaccines. About 40% of the ingested dose accumulates within the intestinal mucosa, making the gut the main target of inflammation and autoimmunity; about 1% accumulates in the skeletal...

  • Article
  • Open Access
3 Citations
2,912 Views
16 Pages

mRNAs containing premature stop codons are responsible for various genetic diseases as well as cancers. The truncated proteins synthesized from these aberrant mRNAs are seldom detected due to the nonsense-mediated mRNA decay (NMD) pathway. Such a sur...

  • Article
  • Open Access
9 Citations
2,426 Views
13 Pages

Human Leucocyte Antigens as Prognostic Markers in Head and Neck Squamous Cell Carcinoma

  • Gerhard Dyckhoff,
  • Christel Herold-Mende,
  • Sabine Scherer,
  • Peter K. Plinkert and
  • Rolf Warta

7 August 2022

Background: The induction and regulation of immune responses depend on human leucocyte antigen (HLA) molecules that present peptides derived from mutated neoantigens or tumor-associated antigens to cytotoxic T cells. The natural variation of HLA mole...

  • Article
  • Open Access
5 Citations
2,775 Views
12 Pages

Proteasomal Processing Immune Escape Mechanisms in Platinum-Treated Advanced Bladder Cancer

  • Michael Wessolly,
  • Fabian D. Mairinger,
  • Thomas Herold,
  • Boris Hadaschik,
  • Tibor Szarvas and
  • Henning Reis

25 February 2022

In recent years, the number and type of treatment options in advanced bladder cancer (BC) have been rapidly evolving. To select an effective therapy and spare unnecessary side effects, predictive biomarkers are urgently needed. As the host’s an...

of 2